An Evolving View of Menopausal Hormone Therapy- Pharmacist


  Credits  1.5

This product is currently out of stock and unavailable.

The controversy over the beneficial effects and safety of hormone therapy (HT) has swung like a pendulum over the last 30 years. Oral conjugated estrogens were first marketed for menopausal symptom relief in the 1930’s. In the 1970’s, HT was cast in a new role as a health-promoting therapy after studies suggested it reduces the risk of heart disease, osteoporosis, and Alzheimer’s disease. Many more women started using HT and were encouraged to do so by their prescribers. In the 1990’s, 2 large clinical trials evaluated HT for the prevention of cardiovascular disease. Unexpectedly, these trials found NO reduction in risk. In fact, the results suggested HT may actually increase the risk of heart disease and breast cancer. Within 6 months after these results were published, more than half of American women who were taking HT stopped. Over the last 3 years, provocative new information has been published suggesting HT may be safer in some women than previously thought. While guidelines, package inserts and “black-box” warnings have not yet changed, the consensus of expert opinion on HT appears to be shifting. This issue will bring you up to date on the risk-benefit profile of HT, including newer information about the risks of heart disease and breast cancer. The established benefits of HT are reviewed, and current recommendations for use are summarized. Tables provide a quick guide to available products and usual doses. The Patient Connection answers questions women frequently ask about HT and includes an inset to help you quickly identify those who should avoid estrogen.


Subscribe and Save. Get access to this course PLUS the Rx Resource Library!

Explore Our Subscription Options

Course Information

Target Audience

Pharm/Nurse Drug Therapy

Knowledge Level

General Overview

This activity will apply to a broad range of learning needs/pharmacy settings. It may include common disease state/therapy overivews and/or general pharmacy needs such as medication errors, immunizations, or law topics.

Learning Objectives

Course Accreditation

  • Activity Type:
  • CE Broker
  • Universal Activity Number:
    Pharmacist : 428-0000-08-007-H01-P
PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

PharmCon, Inc. is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.

In order to obtain a Statement of Credit, attendees must answer poll questions where presented and complete a program evaluation. Attendees may immediately print their Statement of Credit or leave them stored on the website.

Technology Requirements

  • Hardware Requirements
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones
  • Software Requirements
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones
  • Network Requirements
    Broadband Internet Connection:
    T1, Hi-speed DSL or Cable
    4G cellular connection
Computer sharing is NOT permitted due to accreditation guidelines on activity monitoring. Credit is earned by one user per device.